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Abstract 
 
Objective 
To explore whether the IDH1 or 1p/19q status determine the prognostic versus predictive 
role of MGMT promoter methylation in the NOA-04 trial anaplastic glioma biomarker cohort.  
Methods 
Patients (n=183) of the NOA-04 trial with known MGMT and IDH1 status were analyzed for 
interdependency of the prognostic versus predictive role of MGMT promoter methylation from 
IDH1 or 1p/19q status and treatment, using PFS as an endpoint. An independent validation 
cohort of the German Glioma Network (GGN) (n=75) and the NOA-08 trial (n=34) served as 
a confirmation cohort.  
Results 
In tumors with IDH1 mutation, MGMT promoter methylation was associated with prolonged 
PFS with chemotherapy ± radiotherapy (RT) or RT only groups, and thus prognostic. In 
tumors without IDH1 mutation, MGMT promoter methylation was associated with increased 
PFS in patients treated with chemotherapy, too, but not in those who received RT alone as 
the first-line treatment, and is thus chemotherapy-predictive. In contrast 1p/19q codeletions 
showed no such association with the prognostic versus predictive value of MGMT. 
Conclusions 
MGMT promoter methylation is a predictive biomarker for benefit from alkylating agent 
chemotherapy in patients with IDH1-wildtype, but not IDH1-mutant malignant gliomas of 
WHO grades III/IV. Combined IDH1/ MGMT assessment may help to individualize clinical 
decision making in neurooncology.  
Funding  
Charitable Hertie Foundation and National Genome Network of the BMBF 
Keywords 
Anaplastic glioma, IDH1, MGMT, prognosis, WHO grade  
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Introduction 
 
The predictive power of O6-methylguanine DNA-methyltransferase (MGMT) promoter 
methylation for benefit from temozolomide (TMZ) as seen in glioblastoma 1,2 was not 
detected in anaplastic glioma either in the Neurooncology Working Group of the German 
Cancer Society (NOA)-04 trial3 or in the anaplastic oligodendroglial tumor EORTC 26951 
cohort.4,5 Here, MGMT promoter methylation was similarly prognostic for better outcome with 
both alkylating chemotherapy and radiotherapy (RT). 
Among the explanations for these differences is a confounding influence of isocitrate 
dehydrogenase 1 (IDH1) mutations, which are associated with a CpG island methylator 
phenotype in glioma (GCIMP).6 Mutations in IDH1 have been identified in approximately 60 
to 80% of gliomas of WHO grades II and III and in secondary glioblastomas, but only in 
approximately 5% of primary glioblastomas.7,8 Patients with malignant gliomas carrying IDH1 
mutations have a better outcome than patients with IDH1-wildtype gliomas, regardless of the 
specific treatment.1,8-12 Primary glioblastomas without IDH1 mutation are biologically 
different.13 Similarly, also IDH1-wildtype low-grade and anaplastic gliomas are prognostically 
distinct from IDH1-mutated grade II/III gliomas. Importantly, the prognostic properties of all 
markers described so far become apparent only with any form of postoperative genotoxic 
treatment and do not signify the natural postoperative course of disease.12,14  
The present analysis was performed to test the hypothesis that the IDH1 status (mutant 
versus wildtype) rather than histological grading (WHO grade III versus IV) determines 
whether MGMT promoter methylation is prognostic for the benefit from either type of 
genotoxic therapy, RT or chemotherapy, or predictive specifically for benefit from alkylating 
agent chemotherapy.  
  
Wick et al. IDH1/MGMT 
 6 
Patients and Methods 
 
Patients and evaluations – NOA-04 trial - training cohort 
The NOA-04 trial randomized adult patients with histologically confirmed WHO grade III 
anaplastic glioma to either RT (arm A) or alkylating chemotherapy (arms B/C).3 Histologic 
diagnosis of anaplastic glioma was confirmed centrally at the Brain Tumor Reference Center 
in Bonn before study entry according to WHO classifications 199315 and 2000.16 Median 
follow-up time was 54 months. 
 
Standard protocol approvals, registrations, and patients’ consents 
The NOA-04 trial (NCT00717210) was approved by the central ethics committee at the 
University of Tuebingen (106/99) and all 39 partner sites and enrolled patients after written 
informed consent, which included molecular analyses performed with study data and 
materials.  
 
Patients and evaluations – German Glioma Network (GGN) validation cohort 
The GGN is a prospective cohort study that enrolled 2,549 newly diagnosed patients with 
various types of glioma and frozen tissue asservation from October 2004 to October 2010. 
From this cohort we identified 363 patients with a diagnosis of primary anaplastic 
astrocytoma (n=75) or glioblastoma (n=288) confirmed by history taking and central 
pathology review17, as well as adequate follow-up at least until progression, who were 
treated with RT alone or alkylator-based chemo- or radiochemotherapy. Two hundred-thirty-
nine patients were included in previous publications.12,18 Clinical data were prospectively 
documented on CRF and centrally assembled as outlined before 
(http://www.gliomnetzwerk.de).12 The patients were not commonly enrolled into clinical trials, 
and treatment decisions were made by the treating physicians, patients and their families, 
without awareness of results of molecular parameters. Progression was defined locally at 
standardized clinical and MRI examinations19 and not centrally reviewed. All patients gave 
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written informed consent. The review boards of the participating institutions approved all 
activities of the GGN.  
 
Patients and evaluations – the NOA-08 anaplastic astrocytoma biomarker validation cohort 
The NOA-08 trial randomized elderly patients with malignant astrocytoma to primary RT or 
TMZ between 2005 and 2009.20 Patients from this trial with anaplastic astrocytoma as well as 
information on MGMT22 and IDH1 status (Table 1) were pooled with the anaplastic glioma 
cohort of the GGN.  
 
Molecular evaluations 
For subpopulations from the NOA-04 and NOA-08 trials as well a the GGN cohort, for which 
biomaterial was available, MGMT promoter methylation (methylation-specific PCR), 1p/19q 
codeletions (fluorescence in situ hybridization) and IDH mutations (immunohistochemistry for 
IDH1 and sequencing for IDH1/2) status were assessed according to routine methods.3,12 
The NOA-04 subgroup reported here was representative for the per protocol population of 
the trial (Table e-1).  
 
Statistical analyses  
The primary endpoint of NOA-04 was time from surgery to treatment failure (TTF) stratified 
for therapy in the intention-to-treat (ITT) population. Treatment failure was defined as 
withdrawal from therapy before progression after chemotherapy and RT in either sequence 
because of toxicity or poor clinical condition, progression after chemo- and radiotherapy in 
either sequence, or death.3 Secondary end points included progression-free survival (PFS), 
overall survival (OS), and clinical efficacy endpoints (TTF, PFS and OS) stratified for 
histology, 1p/19q co-deletion, MGMT promoter methylation, and IDH1 mutation status. 
Tests used for homogeneity in the NOA-04 biomarker cohort were for age and KPS: 
Wilcoxon-test; for all other variables: Fisher-Exact-test. Missing values were excluded from 
the statistical tests. Here, we focused our analysis on PFS since differentiation between 
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prediction and prognosis was the primary aim of the present post hoc analysis. Univariate 
analysis of PFS used Kaplan-Meier estimates.21 Multivariate analysis used a Cox 
proportional hazards model fitted to adjust for confounding variables. Hazard ratios (HR) with 
95%-confidence intervals were estimated. The analysis was done in two steps. In the first 
step, we used the cohort of the NOA-04 trial to generate hypotheses concerning the role of 
MGMT promoter methylation and IDH1 mutation status as possible prognostic or predictive 
factors for PFS. In the second step, we aimed at confirming these hypotheses in the 
independent GGN/NOA-08 cohort. Analyses for interaction between IDH1 or 1p/19q and 
MGMT status for PFS were done using the Statistical Analysing Programme SAS 9.1.3 and 
IBM SPSS Statistics Release 20.0.0.  
 
  
Wick et al. IDH1/MGMT 
 9 
Results 
Information on MGMT and IDH1 status was available for 183 NOA-04 patients that was used 
as a training cohort. This subgroup was comparable to the group of 91 patients without 
MGMT and IDH1 status data available concerning the distribution of type of primary surgery, 
histology, age and therapy group. The distribution to the RT arm and to the chemotherapy 
arms regarding baseline characteristics was balanced (Table 1). Baseline data for the 
GGN/NOA-08 pooled anaplastic astrocytoma cohort used as a validation cohort commonly 
treated with RT alone (n=42) or chemotherapy ± RT (n=67) is also provided in Table 1.  
In the NOA-04 cohort, PFS was overall longer in patients with IDH1-mutant tumors than in 
patients with IDH1-wildtype tumors (41.6 versus 15.2 months, p<0.0001). Also, PFS was 
longer in patients with MGMT-methylated tumors compared with those with MGMT-
unmethylated tumors (41.6 versus 16.9 months, p<0.0001). To answer the question whether 
the prognostic or therapy modality-predictive impact of MGMT promoter methylation depends 
on the IDH1 status, we compared PFS in the four groups separated by treatment. Patients 
with IDH1-mutant tumors had a longer PFS when the MGMT promoter was methylated, both 
with RT or chemotherapy. In patients with IDH1-wildtype tumors treated with RT, PFS did not 
differ dependent on the MGMT status, but patients without MGMT promoter methylation had 
a dramatically worse PFS when treated with alkylating chemotherapy alone (Table 2). 
Interestingly, a therapy-specific association was neither found for the 1p/19q co-deleted 
patients with (n=71) and without (n=7) IDH1 mutation nor the 1p/19q intact patients with 
(n=55) and without (n=49) IDH1 mutation (data not shown). There were no IDH2 mutations in 
the samples analyzed. For the time-to-treatment failure, which generally meant alkylating 
chemotherapy after failure of RT and RT after failure of chemotherapy, patients with wildtype 
IDH1 benefitted from RT regardless of MGMT status, whereas patients with a methylated 
MGMT promoter showed a larger benefit from chemotherapy. Importantly, patients with 
IDH1-wildtype MGMT methylated tumors, who initially received chemotherapy retain their 
benefit and patients with IDH1-wildtype MGMT methylated tumors, which initially received RT 
showed a benefit matching their MGMT status (Table e-2). Next we performed a multivariate 
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analysis, which included all the previously identified prognostic factors from univariate 
analysis of the NOA-04 trial in addition to MGMT and IDH1, namely resection status 
(complete versus incomplete versus biopsy), histology (astrocytic versus oligodendroglial), 
and age. In the IDH-wildtype group, extent of resection, age and histological subtype were 
prognostic factors. Most importantly, there was an interaction between MGMT status and the 
therapy used; i.e. MGMT promoter methylation predicted benefit from chemotherapy. In 
contrast, in the IDH-mutated group, there was no interaction between MGMT status and 
therapy. Only histological subtype remained as a prognostic factor (Figure 1, Table 3). In 
both groups, there was no prognostic or predictive role for the 1p/19q status (data not 
shown). 
As a next step, we looked at anaplastic glioma patients from the GGN and NOA-0822 cohorts 
to confirm our finding. The only prominent difference in baseline characteristics between the 
RT and the TMZ/RT group was age (Table 1). PFS data from this cohort were plotted 
separated by the use of alkylator-based treatment (RT vs. alkylator-based chemo- or 
radiochemotherapy) and IDH1 mutation as well as MGMT promoter methylation status. 
Patients with IDH1 mutation and MGMT promoter methylation had a surprisingly long PFS > 
5 years for a group of older patients. The small number of patients with the combination of 
IDH1 mutation and absence of MGMT promoter methylation made formal comparison with 
the group of patients with IDH1 mutation and methylated MGMT promoter impossible (Figure 
e-1a,b, Table 4). In contrast, in patients with IDH1-wildtype tumors MGMT promoter 
methylation was not associated with longer PFS when patients were treated with RT alone 
(p=0.598), but linked to significantly longer PFS when alkylating chemotherapy was part of 
the treatment (p=0.018). Analysis for interaction between therapy and MGMT status in an 
analogue Cox-regression model for this validation data set demonstrated a significant 
interaction term for IDH1-wildtype tumors (p=0.039). However, after adjustment to relevant 
clinical parameters the interaction was not significant any more. 
Thus, similar to the anaplastic glioma population of the NOA-04 trial, MGMT promoter 
methylation was only associated with benefit from alkylator-based chemo- and 
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radiochemotherapy (as compared to RT alone) in patients with IDH1-wildtype anaplastic 
gliomas (Figure e-1). Interestingly, these results are further supported by an analysis of 
glioblastoma patients from the GGN cohort. There, a low number of IDH1 mutated tumors 
precludes meaningful conclusions for this patient group, but again MGMT was predictive for 
the effect of alkylating chemotherapy in the IDH1-wildtype tumors (Table e-3).
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Discussion 
Epigenetic silencing of the MGMT gene by promoter hypermethylation and the resulting 
compromise in DNA repair have been associated with longer survival in patients with 
glioblastoma who receive alkylating agents.22,23 In the EORTC 26981/22981/NCIC CE.3 
glioblastoma trial providing evidence for the use of temozolomide, patients with a 
hypermethylated MGMT promoter preferentially benefited from the addition of TMZ to RT.1 
Similarly, hypermethylation of the MGMT promoter was predictive for the response to 
alkylating agent-based (radio-)chemotherapy in elderly patients. In 233 patients with 
glioblastoma > 70 years, patients with MGMT methylated tumors had longer PFS when 
treated with RT plus chemotherapy or chemotherapy alone compared to patients treated with 
RT alone. Patients with MGMT unmethylated tumors appeared to derive no benefit from 
chemotherapy given as primary or salvage treatment.2 These data were readily confirmed in 
the randomized NOA-08 trial which resulted in a practice-changing call for routine MGMT 
testing in elderly glioblastoma patients.20    
NOA-04 challenged the view of a predictive role for MGMT promoter hypermethylation in 
malignant glioma.3 While NOA-04 confirmed the prognostic relevance of MGMT promoter 
methylation, it did not support the suggestion that MGMT promoter methylation is generally 
predictive for benefit from alkylating chemotherapy.1 NOA-04 showed a marked difference in 
PFS between patients with versus without MGMT promoter methylation who were treated 
with RT alone, too. This finding was supported by a reanalysis of the EORTC 26951 trial of 
oligodendroglial anaplastic tumors5, in which also patients with RT only in the standard arm 
had a superior PFS, when the MGMT promoter was hypermethylated. Thus, in anaplastic 
gliomas MGMT promoter methylation is a favourable prognostic marker independent of the 
type of therapy, i.e., radio- or chemotherapy. This pattern might be associated with the high 
incidence of other prognostically favourable molecular markers in these tumors, such as 
IDH1 mutation, 1p/19q co-deletion or yet to be identified novel aberrations. It was concluded 
that MGMT promoter hypermethylation in anaplastic gliomas may be regarded as (i) a 
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 13 
prognostic marker for good outcome in patients treated with RT or any type of genotoxic 
therapy or (ii) predictive for response to RT itself.3,24  
The R132 mutations in the IDH1 gene represent the most recent and to date strongest 
positive outcome marker in anaplastic gliomas that will likely influence histopathological 
grading as a subclassifier in the group of malignant gliomas as well as stratification in the 
future trials on anaplastic gliomas and may lead to a better understanding of the differences 
between anaplastic glioma and glioblastoma.18 Already the original publication on IDH1 
mutations in glioblastomas had indicated that tumors carrying IDH1 mutations had a better 
prognosis than IDH1-wildtype tumors.25 This has been confirmed across gliomas of WHO 
grades II-IV, including both astrocytic and oligodendroglial tumors.3,9,20 In contrast, it has not 
been possible to link IDH1 mutations to better responsiveness to specific types of treatment, 
neither in glioblastoma12 nor in anaplastic gliomas in the NOA-043 or the EORTC 26951 
trial.11 Moreover, in patients with low-grade gliomas IDH1 mutations were linked to improved 
overall survival, but not to response to TMZ at progression after RT.14,26 The frequency of 
IDH1 mutation is between 50-70% in WHO grade III, 5-10% in WHO grade IV gliomas of 
younger patients and almost zero in elderly patients with glioblastoma.7,24  
The present analysis from the NOA-04 trial suggests an interesting and simple interaction 
model to explain the discrepancy of the relevance of the MGMT status in WHO grade III and 
IV gliomas. According to our data, MGMT promoter methylation is prognostic for patients with 
IDH1-mutant WHO grade III gliomas. In contrast, in patients with IDH1-wildtype tumors, 
MGMT promoter methylation is predictive for benefit from alkylating chemotherapy (Figure 1, 
Tables 2-4). This finding not only provides a good explanation for a long-standing conflict that 
proposed a principal difference between WHO grade III and WHO grade IV tumors but also 
suggests the necessity of testing for both, IDH1 mutations and methylation status of the 
MGMT promoter. Patients with anaplastic gliomas carrying wildtype IDH1 and a 
hypermethylated MGMT promoter may not be adequately treated with RT alone, but should 
be considered candidates for alkylating chemotherapy with TMZ or PCV, or be treated within 
one of the current trials (e.g. CATNON) for combined radiochemotherapy with TMZ. IDH1 
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mutational status rather than the WHO grade may more precisely determine whether the 
MGMT promoter status is predictive for benefit from alkylating chemotherapy. Interestingly, a 
similar interaction was not found for 1p/19q and MGMT status, but the absence of a 1p/19q 
co-deletion conferred a worse prognosis in RT- and also chemotherapy-treated patients 
(data not shown). However, 1p/19q co-deletion has been developed as a strong predictive 
biomarker by long-term analysis of the EORTC 2695127 and RTOG 94-0228 trials and 
therefore needs to be included into the biomarker panel, which is of immediate relevance for 
anaplastic glioma patients.  
The current analyses were limited by sample and event number to a two-factor interaction 
term. This is mirroring the clinical situation, where IDH information will be available and the 
decision to test for MGMT and to make a treatment decision will follow. In addition to the 
limited sample sizes, the post hoc hypothesis-generating character of this data and the 
limitations of the supporting data set, the present analysis leaves some questions 
unanswered. What is the biological basis for the prognostic value of IDH1 mutations in 
patients treated with RT? Is there a patient cohort that should be treated with combined 
radiochemotherapy or may chemotherapy alone be sufficient? Is there a differential role of 
these biomarkers in one of the histological subgroups? The first question will most likely be 
answered in the near future in the context of the association between IDH1 mutations and 
the so-called GCIMP, where tumors with IDH1 mutations build a distinct subset of samples 
displaying concerted hypermethylation at a large number of loci.29,30 In a subgroup analysis 
of EORTC 26951, GCIMP status correlated with survival, MGMT promoter hypermethylation, 
1p/19q co-deletion, and IDH1 mutation status. GCIMP status strongly increased the 
predictive accuracy of survival in a model including known clinical prognostic factors such as 
age and performance score.31 The strong association between GCIMP status and MGMT 
promoter methylation suggested that the MGMT promoter methylation status is part of a 
more general, prognostically favorable genome-wide methylation profile, which most likely 
includes radiosensitivity makers. Discovery of these markers may help identifying anaplastic 
glioma patients that benefit from RT and could further open opportunities for targeted 
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manipulation of the underlying pathways. Despite evidence for a mere alkylator therapy-
predictive role for MGMT status from three randomized trials with RT-only and alkylator-
based arms1,20,32, there is also conflicting data from a large retrospective analysis of an MD 
Anderson cohort. In the latter analysis, there was some prognostic effect of MGMT status for 
glioblastoma patients treated with RT alone.33   
The present data are meant to generate an interesting hypothesis and to challenge the way 
that we are dealing with biomarker information, not marker by marker as in the past and even 
presently in the EORTC 2695127 and RTOG 94-0228 publications, but by acknowledging the 
interaction of the data that we know of. 
The present data from NOA-04, GGN and NOA-08 will provoke a discussion on the 
standard-of-care arm, RT, in the IDH1-wildtype, MGMT promoter-hypermethylated patients 
of the CATNON trial, as well as on the TMZ alone arm in the halted CODEL trial for patients 
with unmethylated tumors despite the low frequency of 1p/19q codeleted/MGMT 
unmethylated tumors. In these trials, the standard arm is RT and the role of TMZ in patients 
with anaplastic gliomas without 1p/19q codeletion (CATNON) or with the codeletion (CODEL) 
is investigated. Similar, there will be a discussion on the standard-of-practise also outside 
trials. Data from these trials may further validate the role of MGMT as a predictive biomarker 
in the IDH1-wildtype patient population. It may confirm that alkylating chemotherapy 
produces no benefit in patients with unmethylated, IDH1-wildtype tumors, but will provoke the 
question whether TMZ alone with deferred RT may be a sufficient treatment in patients with 
MGMT promoter methylated and IDH1-wildtype tumours.  
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Figure Legend 
 
Figure: Kaplan-Meier survival estimates in the NOA-04 biomarker cohort. PFS is shown 
by IDH1 mutation status (mutated or wildtype) and MGMT promoter methylation status 
(MGMT promoter methylated (MGMT+) or unmethylated (MGMT-) for RT-treated patients 
(blue lines) or chemotherapy-treated patients (red lines). In this cohort 25 events were 
censored in the RT and 16 in the chemotherapy groups, respectively. Vertical lines on the 
Kaplan-Meier curves indicate this. 
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Table 1. Baseline Patient Characteristics 
 NOA-04 training cohort NOA-08/GGN validation cohort 
 RT 
(n = 91) 
PCV or TMZ 
(n = 92) 
RT  
(n =42) 
TMZ ± RT 
(n =67) 
Median age (range), years 44 (23-74) 42 (20-77) 67 (23-75) 50 (23-80) 
Central histopathology, n 
Anaplastic astrocytoma 
Anaplastic oligoastrocytoma 
Anaplasticoligodendroglioma 
 
40 
34 
17 
 
41 
38 
13 
 
32 
9 
1 
 
45 
19 
3 
Median KPS (range) [%] 
   Unknown, n 
100 (70-100) 100 (70-100) 90 (80-100) 
6 
90 (50-100) 
5 
Resection, n 
Total 
No total  
Biopsy 
Unknown 
 
39 
43 
9 
 
32 
47 
13 
 
15 
21 
 5 
 1 
 
29 
33 
4 
1 
Co-deletion of 1p/19q, n 
Yes 
No 
Missing 
 
36 
46 
9 
 
32 
48 
12 
 
NA 
 
NA 
MGMT promoter, n 
methylated 
unmethylated 
 
55 
36 
 
61 
31 
 
31 
11 
 
47 
20 
IDH1, n 
wildtype 
mutant 
 
30 
61 
 
30 
62 
 
24 
18 
 
33 
34 
Abbreviations: German Glioma Network (GGN), isocitrate dehydrogenase (IDH), Karnofsky Performance Score (KPS), O6-methyl-guanyl 
methyltransferase (MGMT), not available (NA), procarbazine/CCNU/vincristine (PCV), radiotherapy (RT) 
(Tests for homogeneity: Age and KPS: Mann-Whitney-U-Test; other variables: Fisher-Exact-Test) 
*There were no IDH2 mutations in the samples examined from the NOA-04 cohort. 
Baseline characteristics differed significantly (p=0.027) for median age in the GGN/NOA-08 validation cohort . 
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Table 2.  Progression-free survival NOA-04 Biomarker Cohort 
  RT  Chemotherapy  
  Median (95% CI), months N Median (95% CI), months N 
IDH1-mutant MGMT methylated  36.8 (34.4-NR) 45 44.7 (34.7 - NR) 47 
 MGMT unmethylated  28.0 (10.9 - NR) 16 28.1 (7.4 – NR) 15 
IDH1-wildtype MGMT methylated  16.3 (4.9 – 23.6)* 10 27.2 (8.7 – 50.0)** 14 
 MGMT unmethylated  17.2 (9.6 – 34.2)* 20 9.1 (6.8 – 17.1)** 16 
Abbreviations: confidence interval (CI), isocitrate dehydrogenase (IDH), O6-methyl-guanyl methyltransferase (MGMT), not reached (NR), 
radiotherapy (RT) 
 
*LogRank-test for methylation effect (RT- IDH1-wildtype), p=0.331 
**LogRank-test for methylation effect (chemotherapy), p=0.016  
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Table 3. Prognostic Model for the NOA-04 Biomarker Cohort 
NOA-04 Biomarker Cohort  
IDH-wildtype 
(n=60, 51 with progression) 
 Cox regression 
Variable (Risk)  Hazard ratio 95%-CI P 
Progression-free survival     
Biopsy or incomplete vs. complete resection 
Age in yrs. 
Astrocytoma vs. oligodendroglial tumor 
Chemotherapy vs. RT 
MGMT methylated vs. unmethylated 
Interaction MGMT*Therapy 
 2.35 
1.04 
3.63 
3.02 
2.02 
0.11 
1.24-4.44 
1.01-1.06 
1.74-7.55 
1.40-6.49 
0.84-4.89 
0.03-0.40 
0.009 
0.004 
0.001 
0.005 
0.117 
0.001 
NOA-04 Biomarker Cohort  
IDH-mutated 
(n=123, 58 with progression) 
 Cox regression 
Variable (Risk)  Hazard ratio 95%-CI P 
Progression-free survival     
Biopsy or incomplete vs. complete resection 
Age in yrs. 
Astrocytoma vs. oligodendroglial tumor 
Chemotherapy vs. RT 
MGMT methylated vs. unmethylated 
Interaction MGMT*Therapy 
 1.14 
1.01 
2.50 
1.34 
0.66 
0.80 
0.65-1.99 
0.99-1.04 
1.39-4.49 
0.52-3.44 
0.29-1.52 
0.26-2.47 
0.658 
0.401 
0.002 
0.540 
0.334 
0.697 
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Abbreviations: confidence interval (CI), isocitrate dehydrogenase (IDH), Neurooncology Working Group of the German Cancer Society (NOA), O6-
methyl-guanyl methyltransferase (MGMT), radiotherapy (RT) 
 
Prognostic factors in the NOA-04 trial were: age, extent of resection, 1p/19q status, MGMT status and IDH status.3 In the present analysis of the 
biomarker cohort, the factor extent of resection was no longer prognostic in both arms and age as well as histological subtype are no longer 
prognostic in the RT arm of this biomarker subset of patients.  
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Abbreviations: confidence interval (CI), German Glioma Network (GGN), isocitrate dehydrogenase (IDH), Neurooncology Working Group of the 
German Cancer Society (NOA), O6-methyl-guanyl methyltransferase (MGMT), radiotherapy (RT) 
 
*LogRank-test for difference: p=0.598 
**LogRank-test for difference: p=0.018 
Table 4.  Progression-free survival in the GGN Anaplastic Astrocytoma / NOA-08 Cohort 
  RT  Chemotherapy ± RT  
  Median (95%-CI), months N Median (95%-CI), months N 
IDH1-mutant MGMT methylated 71.5 (48.3-94.8) 17 56.5 (34.2-78.9) 32 
 MGMT unmetylated - 1 - 2 
IDH1-wildtype MGMT methylated 5.3 (3.7-6.8)* 14 15.8 (2.5-29.1)** 15 
 MGMT unmethylated 9.3 (5.2-13.4)* 10 3.4 (2.0-4.8)** 18 
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Supplementary Tables 
 
Table e-1: TTF and PFS 
NOA-04 cohort Per Protocol 
Radiotherapy 
(n = 139) 
Biomarker 
Radiotherapy 
(n=91) 
Per Protocol 
PCV or temozolomide 
(n = 135) 
Biomarker 
PCV or temozolomide 
(n=92) 
Median time-to-treatment 
failure, months (95%-CI) 
 Astrocytoma 
 Oligoastrocytoma 
 Oligodendroglioma 
40.4+ 
 
32.0 (23.3-NR) 
NR 
NR 
42.7+ 
 
32.9 (23.8-NR) 
42.7+ 
NR 
43.8 (37.4-NR) 
 
29.4 (19.0-42.0) 
NR 
52.6 (29.8-NR) 
43.5 (33.0-NR) 
 
21.6 (13.5-37.4) 
NR 
52.6 (29.8-NR) 
Treatment failure at 48 
months, % (95% CI) 
55.5 (46.3-64.6) 59.8 (48.7-70.9) 46.4 (36.7-56.1) 46.7 (35.5-58.0) 
Median progression-free 
survival, months (95%-CI) 
 Astrocytoma 
 Oligoastrocytoma 
 Oligodendroglioma 
30.6 (16.3-42.8) 
 
10.8 (8.9-28.3) 
52.1 (18.4-NR) 
47.6 (34.6-NR) 
34.2 (18.4-47.6) 
 
16.3 (8.9-30.6) 
51.0 (14.9-NR) 
47.6 (25.7-NR) 
31.9 (21.1-37.3) 
 
18.2 (12.1-24.2) 
52.7 (32.8-NR) 
21.4+ 
31.2 (19.6-39.1) 
 
15.7 (8.7-20.6) 
50.0 (31.9-NR) 
33.9 (12.0-NR) 
Abbreviations: confidence interval (CI), not reached (NR), procarbazine/CCNU/vincristine (PCV), progression-free survival (PFS), time-to-treatment 
failure (TTF), radiotherapy (RT)
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Table e-2.  Time-to-treatment failure in the NOA-04 Biomarker Cohort 
  RT  Chemotherapy  
  Median (95% CI), 
months 
N Median (95% CI), 
months 
N 
IDH1-mutant MGMT methylated  >54 (45.4-NR) 45 49.7 (43.7 - NR) 47 
 MGMT unmethylated  >54 (NR - NR) 16 >54 (47.4 – NR) 15 
IDH1-wildtype MGMT methylated  33.3 (28.9 – 38.1) 10 35.8 (20.7 – 52.0) 14 
 MGMT unmethylated  25.2 (16.6 – 34.9) 20 16.1 (10.8 – 20.5) 16 
Abbreviation: confidence interval (CI), not reached (NR), radiotherapy (RT) 
 
 
 
 
Table e-3.  Progression-free survival in the GGN Glioblastoma Cohort 
  RT 
 
 Chemotherapy 
± RT 
 
  Median (95%-CI), 
months 
N Median (95%-CI), 
months 
N 
IDH1-mutant MGMT methylated 18.1 (0-44.8) 7 31.7 (18.3-45.1) 13 
 MGMT unmetylated - 1 12.8 (2.2-23.5) 5 
IDH1-wildtype MGMT methylated 5.5 (3.4-7.6) 28 10.0 (5.1-14.8) 87 
 MGMT unmethylated 6.2 (5.8-6.6) 38 6.1 (5.1-7.1) 109 
 
Abbreviations: confidence interval (CI), radiotherapy (RT) 
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Supplementay Figures 
 
Figure e-1a – Radiotherapy 
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Figure e-1b – Alkylating chemotherapy with or without radiotherapy 
 
 
 
Figure Legends 
 
Figure e-1: Kaplan-Meier survival estimates for the anaplastic astrocytoma cohort 
from the pooled NOA-08/GGN cohorts. PFS data plotted by IDH1 mutation status 
(mutated or wildtype) and MGMT promoter methylation status (MGMT promoter 
methylated (MGMT+) or unmethylated (MGMT-) for patients treated with RT (panel a) 
or chemotherapy/radiochemotherapy (panel b). One patient with RT and IDH1 
mutation and no MGMT promoter methylation had PD after twenty months. This 
curve is not shown in panel a. In panel b the curve for two patients with IDH1 
mutation and no MGMT promoter methylation is also not shown (PD after 50 months 
and censored time after 74 months). In this cohort 11 events were censored in the 
RT and 19 in the RT ± chemotherapy groups, respectively. This is indicated by 
vertical lines on the Kaplan-Meier curves. 
IDH1-wildtype / 
MGMT unmethylated (n=18) 
IDH1-wildtype / 
MGMT methylated (n=15) 
IDH1-mutated / 
MGMT unmethylated (n=32) 
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